Veraxa Biotech AGNASDAQ: VRXA

VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Partnership

· Issued by Veraxa Biotech AG

Summary by 6ix AI

VERAXA Biotech, which develops cancer therapies, has started cell line development for its lead BiTAC T-cell engager program, its most advanced cancer candidate. It selected ATUM to generate stable clonal cell lines, meaning uniform cell populations used in manufacturing, with ATUM's Leap-In Transposase technology.

Key details

  • ATUM is a U.S.-based contract research organization, a company hired to carry out research work, that specializes in bioengineering and cell line development.
  • The work is meant to support manufacturing, analytical development and nonclinical studies, meaning testing done before any human trials, that are required before clinical testing.
  • VERAXA says its BiTAC platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity linked to conventional approaches.
  • VERAXA has expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as several of its cancer programs move toward clinical development.

What’s still pending

  • The candidate is still advancing toward IND/CTA-enabling studies. These are the studies needed before filing applications with regulators to start human trials. It has not yet entered clinical testing.

6ix AI wrote this summary from the release below and checked it against the release.

Featured Image

Austin, Texas, United States, July 9th, 2026, FinanceWire

  • The company has initiated cell line development for its lead BiTAC(R) T-cell engager program, selecting ATUM to support manufacturing development as the candidate advances toward IND/CTA-enabling studies.
  • ATUM will apply its Leap-In Transposase(R) technology to generate stable clonal cell lines for VERAXA's lead therapeutic candidate.
  • The collaboration represents an important development milestone, supporting manufacturing, analytical development and nonclinical studies required before clinical testing.
  • VERAXA's BiTAC(R) platform is designed to improve the selectivity of T-cell engagers, potentially reducing toxicity associated with conventional approaches.
  • The company recently expanded its research facilities in Heidelberg, Germany, increasing laboratory capacity as multiple oncology programs move toward clinical development.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has begun cell line development for its lead BiTAC(R) T-cell engager ("BiTAC(R)-TCE") program, marking another step in preparing the company's most advanced oncology candidate for future clinical development.

The company announced that it has selected ATUM, a U.S.-based contract research organization specializing in bioengineering and cell line development, to generate stable clonal cell lines using its proprietary Leap-In Transposase(R) technology. According to VERAXA, the collaboration is intended to...

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA

Contact
IBNwww.InvestorBrandNetwork.comEditor@InvestorBrandNetwork.com

Veraxa Biotech AG on 6ix

Earlier from Veraxa Biotech

Later from Veraxa Biotech

All Veraxa Biotech news releases